Antibody data
- Antibody Data
- Antigen structure
- References [1]
- Comments [0]
- Validations
- Western blot [1]
- Immunohistochemistry [1]
- Other assay [3]
Submit
Validation data
Reference
Comment
Report error
- Product number
- PA5-19165 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- P2X7 Polyclonal Antibody
- Antibody type
- Polyclonal
- Antigen
- Synthetic peptide
- Description
- This antibody is predicted to react with canine, mouse and rat based on sequence homology. This antibody is tested in Peptide ELISA: antibody detection limit dilution 16,000.
- Reactivity
- Human, Mouse
- Host
- Goat
- Isotype
- IgG
- Vial size
- 100 µg
- Concentration
- 0.5 mg/mL
- Storage
- -20° C, Avoid Freeze/Thaw Cycles
Submitted references Pharmacological inhibition of P2RX7 ameliorates liver injury by reducing inflammation and fibrosis.
Baeza-Raja B, Goodyear A, Liu X, Lam K, Yamamoto L, Li Y, Dodson GS, Takeuchi T, Kisseleva T, Brenner DA, Dabbagh K
PloS one 2020;15(6):e0234038
PloS one 2020;15(6):e0234038
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- PA5-19165 (0.3 µg/mL) in Human Brain (Frontal Cortex) lysate with (B) and without (A) blocking with the immunising peptide, the primary antibody incubation was 1 hour and detected by chemiluminescence.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunohistochemical analysis of P2X7 in paraffin embedded human cortex using a P2X7 polyclonal antibody (Product #PA5-19165) at a concentration of 3.8 µg/mL. Steamed antigen retrieval was performed with pH 6 buffered citrate. Samples were then stained with alkaline phosphatase.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Fig 1 P2RX7 and inflammasome activation are increased in NASH-affected liver. (A) Representative images (objective 2X) of Sirius red staining (top) and immunohistochemical staining (objective 40X) of P2RX7 (bottom) in liver tissue from a representative control and NASH-affected donor with quantification of Sirius red + area and P2RX7 + cells ( n = 5 individuals per group; n = 6-8 images per donor). Scale bar, 100 muM. Black arrows highlight P2RX7 + cells. (B) Quantification of CD45 + , CD45 + / P2RX7 + , CD14 + , CD14 + / P2RX7 + , CD68 + , CD68 + / P2RX7 + cells ( n = 5 individuals per group; n = 6-8 images per donor). (C) IL-1beta, (D) caspase-1, (E) CCL2, and (F) CCL5 levels in liver tissue from control and NASH-affected liver biopsies ( n = 5 individuals per group). (G) Relative expression levels of P2RX 7, NLRP3 , AIM2 , ASC , CASP1 , IL-1beta and (H) CD11b , CD45 , Tnfalpha , Il-6 , CCL2 , CCL5 in liver tissue from control and NASH-affected donors ( n = 5 individuals per group). n.d., for not detected. In all statistical plots, the data are shown as the mean +- SEM. * P
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Fig 8 Pharmacological inhibition of P2RX7 protects against inflammation and fibrosis in a CCl 4 -induced liver fibrosis model in non-human primates. (A) Schematic representation of the timing strategy used to evaluate the effects of pharmacological inhibition of P2RX7 with SGM-1019 in CCl 4 -induced liver fibrosis in monkeys. (B) Representative images of H&E (objective 20X), Sirius red-stained and alphaSMA (objective 10X) expression determined by immunohistochemistry in liver sections from monkeys. Scale bar, 50 muM for H&E and 100 muM for Sirius red and alphaSMA. (C) Total histological score from liver sections. (D) Percentage of Sirius red staining area. (E) Quantification of alphaSMA expression in liver sections. (F) Relative expression of COL1 alpha1 and COL1 alpha2, and ( G ) CD45 in the livers from monkeys. (H) Serum levels of ALT and AST in monkeys after treatments. In all statistical plots, the data are shown as the mean +- SEM. * P